

An injectable, self-healing and MMP-inhibiting hyaluronic acid gel via iron coordination

GAO, Ziyu, YANG, Xuebin, JONES, Elena, BINGHAM, Paul <http://orcid.org/0000-0001-6017-0798>, SCRIMSHIRE, Alex <http://orcid.org/0000-0002-6828-3620>, THORNTON, Paul and TRONCI, Giuseppe

Available from Sheffield Hallam University Research Archive (SHURA) at:

https://shura.shu.ac.uk/27389/

This document is the Accepted Version [AM]

Citation:

GAO, Ziyu, YANG, Xuebin, JONES, Elena, BINGHAM, Paul, SCRIMSHIRE, Alex, THORNTON, Paul and TRONCI, Giuseppe (2020). An injectable, self-healing and MMP-inhibiting hyaluronic acid gel via iron coordination. International Journal of Biological Macromolecules, 165 (B), 2022-2029. [Article]

Copyright and re-use policy

See http://shura.shu.ac.uk/information.html

1 An injectable, self-healing and MMP-inhibiting hyaluronic acid gel via iron coordination

- 2 Ziyu Gao,^{1,2} Xuebin Yang,¹ Elena Jones,³ Paul A. Bingham,⁴ Alex Scrimshire,⁴ Paul D. Thornton,^{2,*}
- 3 Giuseppe Tronci^{1,5,*}

4 ¹ School of Dentistry, St. James's University Hospital, University of Leeds, UK

- 5 ^{*} E-mail: <u>g.tronci@leeds.ac.uk</u>
- 6 ² School of Chemistry, University of Leeds, Leeds, UK
- 7 * E-mail: p.d.thornton@leeds.ac.uk
- 8 ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, UK
- 9 ⁴ Materials and Engineering Research Institute, Sheffield Hallam University, UK

⁵ Clothworkers' Centre for Textile Materials Innovation for Healthcare, School of Design,

- 11 University of Leeds, UK.
- 12

13 Abstract

14 Regulating the activity of matrix metalloproteinases (MMPs) is a potential strategy for 15 osteoarthritis (OA) therapy, although delivering this effect in a spatially and temporally 16 localised fashion remains a challenge. Here, we report an injectable and self-healing hydrogel 17 enabling factor-free MMP regulation and biomechanical competence in situ. The hydrogel is 18 realised within one minute upon room temperature coordination between hyaluronic acid 19 (HA) and a cell-friendly iron-glutathione complex in aqueous environment. The resultant gel 20 displayed up to 300% in shear strain and tolerance towards ATDC 5 chondrocytes, in line with 21 the elasticity and biocompatibility requirements for connective tissue application. 22 Significantly enhanced inhibition of MMP-13 activity was achieved after 12 hours in vitro, 23 compared with a commercial HA injection (OSTENIL® PLUS). Noteworthy, 24-hour incubation 24 of a clinical synovial fluid sample collected from a late-stage OA patient with the reported 25 hydrogel was still shown to downregulate synovial fluid MMP activity (100.0 \pm 17.6 % \rightarrow 26 81.0±7.5 %), with at least comparable extent to the case of the OSTENIL® PLUS-treated SF 27 group (100.0 \pm 17.6 % \rightarrow 92.3 \pm 27.3 %). These results therefore open up new possibilities in the 28 use of HA as both mechanically-competent hydrogel as well as a mediator of MMP regulation 29 for OA therapy.

Keywords: Hyaluronic acid, iron-glutathione complex, injectable hydrogel, synovial fluid,
 osteoarthritis, MMP-13 inhibition.

32

33 Introduction

Osteoarthritis (OA) is a chronic and irreversible disease which results in continuous cartilage degradation, increased joint friction, and pain. The onset and progression of OA is closely linked to proteolytic imbalances, whereby upregulated activity of matrix 37 metalloproteinases (MMPs), particularly MMP-13 (collagenase), results in the pathological 38 breakdown of articular cartilage (Yoshihara et al., 2000) (Burrage et al., 2006) (H. Li et al., 39 2017). MMP-13 concentration strongly correlates to vascular endothelial growth factor 40 (VEGF) concentration, which plays an important role in angiogenesis and can serve as a 41 biomarker for OA diagnosis and therapeutic monitoring (Kim et al., 2011). In addition, the 42 overexpression of MMP-13 is found in advanced osteoarthritic synovial fluid (Heard et al., 43 2012). Injectable, non-cytotoxic and biomechanically viable materials that are able to inhibit 44 MMP-13 are highly sought to restore tissue homeostasis and minimise the risks of knee 45 replacement (M. Wang et al., 2013).

46 Injectable materials enable the delivery and localisation of therapeutic compounds at a 47 target diseased site. In particular, injectable materials that mimic the features of the 48 extracellular matrix (ECM) are ideal therapeutic scaffolds since they enable cell attachment, 49 proliferation and temporally controlled mechanical function with minimal toxic effect 50 following degradation (Stevens & George, 2005) (Blache et al., 2020). As such, they have been 51 widely employed as carriers for improved mesenchymal stem cell (MSC) delivery for bone 52 repair and OA management (M. Liu et al., 2017). Hydrogel systems that contain synthetic 53 polymers have shown promise as materials for OA management due to their injectability and 54 versatility in presenting bioactive functionalities that downregulate MMP activity and prolong 55 the activity of encapsulated MSCs (Clark et al., 2020). Yet, the limited degradability of many 56 synthetic polymers and the demands of polymer synthesis make their translation to 57 commercial products challenging. The design of injectable hydrogels from ECM-derived 58 polymers that can correct proteolytic imbalances may provide an alternative cell-free and 59 regulatory-friendly strategy for OA management, which avoids non-biodegradable synthetic 60 polymers.

61 Hyaluronic acid (HA) is an anionic non-sulfated glycosaminoglycan that constitutes one of 62 the main components of cartilaginous ECM (Slepecky, 1967). Due to its polysaccharide 63 backbone, a great deal of attention has been put into investigating HA functionalisation for 64 targeted applications, aiming to accomplish tuneable physicochemical properties (Zamboni et 65 al., 2020) and improved cell viability (Zamboni et al., 2017). However, many commercially 66 available HA-based products are in the form of injectable materials, for instance OSTENIL® 67 PLUS, which is routinely applied in the clinic for the treatment of osteoarthritic joints. 68 Significantly improved knee function and pain relief were confirmed through the Visual Analog 69 Scale (VAS) score and the Western Ontario and McMaster Universities Osteoarthritis Index 70 (WOMAC) score (Kotevoglu et al., 2006)(Dernek et al., 2016). HA injections are usually 71 suggested to be delivered every 1-2 weeks to the joint cavity, although they are unable to 72 control OA-related MMP upregulation. Despite HA's capability to interact with and stimulate 73 chondrocytes in vivo, these products are only designed to offer a palliative, short-lived 74 biomechanical solution that is used as a last resort prior to joint replacement. Intelligent HA

formulations that include therapeutics for OA treatment through MMP-13 inhibition, and retain mechanical stability, are highly sought. To pursue this vision, a cell-friendly ironglutathione (Fe³⁺-GSH) complex recently reported by our group (Gao et al., 2020) was investigated for use as both a crosslinker of HA to yield an injectable hydrogel, and as a potential therapeutic to inhibit MMP-13 activity, exploiting the competitive metalcoordinating reaction between thiol complexed iron (Fe³⁺) and free sulfhydryl groups of active MMPs.

82 Although some effort afforded the creation of HA-containing gels via metal coordination, 83 e.g. INTERGEL[™], unpleasant side-effects and serious complications experienced by many 84 patients call for new safer alternatives (Tang et al., 2006). To prevent tissue damage from OH 85 and peroxy-type radicals, which could be generated during hyaluronic acid degradation 86 (Katarina Valachová et al., 2016; Katarína Valachová et al., 2015), it is important to involve 87 reductive components into the HA-based therapeutic material, for example, thiol groups 88 (Katarína Valachová et al., 2015). In this case, introducing cell friendly Fe³⁺-GSH complex into 89 HA hydrogels is worth investigating.

90 Hydrogel injectability has been pursued via dynamic covalent chemistries in biopolymer-91 based hydrogels for tissue engineering, including Schiff-base reactions (Huang et al., 2016; S. 92 Li et al., 2020), Diels-Alder reactions (DA) click coupling reactions (Hu et al., 2019) (Spicer, 93 2020), as well as via thermal gelation mechanisms (Zhang et al., 2019; Lee et al., 2020) 94 compliant with injection-mediated delivery. On the one hand, the formation of covalently 95 crosslinked hydrogels with appropriate mechanical properties in physiological conditions to 96 reduce joint friction has up to now proven challenging. This is largely due to the fact that the 97 presence of covalent crosslinks reduces hydrogel's dynamic tensile, compressive and shear 98 strain, limiting hydrogel's ability to bear multiple load-bearing cycles, as in the case of articular 99 cartilage. On the other hand, although thermosensitive polymer formulations have been 100 developed, only a limited number have been made with HA formulations free of the synthetic 101 polymer phase (Zhang et al., 2019).

102 Other than covalent networks, redox-based self-healable and injectable polymer hydrogels 103 were achieved that can withstand relatively high shear strain (~50 %) (Chen et al., 2019) (L. 104 Liu et al., 2019). Likewise, metal-coordinated hybrid materials have been reported serving as 105 electroconductive materials (Shi et al., 2015), catalyst supports (Loynachan et al., 2019), and 106 for magnetic resonance imaging (Paquet et al., 2011) (H. Wang et al., 2019). Ultimately, 107 composite hydrogels have been made of multiple biopolymers and bioglass and ionically 108 crosslinked by calcium dications (Yu et al., 2019). The composite material is able to withhold 109 quercetin, an MMP inhibitor, so that 70% reduction in MMP-13 expression was reported after 110 48 hours, which proved key to induce cartilage repair after 12 weeks in vivo. These studies 111 provide novel design concepts that harness the functionalities of metals and peptides, aiming

to build simple ECM mimetics with flexible mechanical properties and MMP inhibitioncapability.

In this work, the straightforward creation of a non-toxic HA-based hydrogel that is 114 injectable and self-healing is reported. HA combined with an iron (III)-glutathione (Fe³⁺-GSH) 115 116 complex results in the formation of a physical hydrogel upon co-injection. We hypothesised 117 that hydrogel-induced MMP inhibition was accomplished by harnessing the metal-118 coordinating reaction between thiol-complexed iron(III) and the free sulfhydryl groups of 119 active MMPs. Crucially, the Fe³⁺-GSH complex has the dual function of being the crosslinker 120 within the hydrogel, and also providing a therapeutic effect for inhibiting MMP activity, as 121 confirmed with synovial fluid clinical samples collected from patients with late-stage OA. 122 Consequently, the hydrogel may act as a self-healable scaffold that reduces joint friction and 123 halts cartilage degradation, whilst boosting local cell function. Delivery of this system in situ 124 has significant potential in OA therapy, aiming to prevent the degradation of cartilage whilst 125 correcting growth factor concentrations and cellular activity towards cartilage repair.

126

127 **2. Materials and methods**

The hyaluronic acid sodium salt (molecular weight: 1,200 kDa, cosmetic grade) was purchased from Hollyberry Cosmetic. L-glutathione (reduced) was purchased Alfa Aesar. Alamar Blue assay kit was from ThermoFisher Scientific. Human recombinant Pro-MMP 13 was purchased from Antibodies.com, and the MMP activity assay kit (Fluorometric Green, ab112146) was from ABChem. All the other reagents were provided by Sigma-Aldrich.

133 Rheology of HA solutions supplemented with Fe³⁺-GSH

Different concentrations of Fe³⁺-GSH complex were added to the HA solution (**Table S1**) to achieve the optimal, most stable, hydrogel. To exclude the influence of HA concentration on gel formation, the final concentration of HA in the gel-forming mixture was controlled to 1.33 wt.% by addition of deionised water. All test group samples were named as "Fe xxx", in which "xxx" corresponds to the volume of Fe³⁺-GSH solution (μ L) in the HA solution (mL). All control samples were named as "Ctrl xxx", in which "xxx" corresponds to the volume (μ L) of Fe³⁺-GSH solvent (120 mM HCl) per mL of HA solution.

The Fe³⁺-GSH-supplemented HA solution was injected onto an MCR 302 Rheometer (Anton
Paar) and pressed by a 25 mm parallel plate (1.5 mm gap) at 37 °C with a variable shear rate
to study the viscosity of hydrogels formed with different Fe³⁺-GSH complex content.

144 Preparation of Fe³⁺-GSH self-healing HA hydrogel (Fe 300)

145 The Fe³⁺-GSH complex was prepared using our previous method (Gao et al., 2020). Briefly, 146 123 mg (0.4 millimoles) of GSH was added to 4 mL FeCl₃ aqueous solution (0.1 M), and the

147 mixture was mildly agitated by vortex mixing for 2 min until the solution became yellow. Then,

the complex was precipitated by adding 40 mL of ethanol (×3) and collected by centrifugation
 at 10,000 rpm for 15 min. The Fe³⁺-GSH complex was dried at 37 °C for further use.

10 mg of Fe³⁺-GSH complex was dissolved in 1 mL HCl solution (120 mM). Each 300 µL 150 Fe³⁺-GSH complex solution was added to 1 mL hyaluronic acid solution (2 wt.%) and stirred at 151 152 room temperature for 1 min to obtain a self-healing hydrogel (Fe³⁺-GSH gel). The self-healing 153 behaviour of all hydrogels formed was characterised by determining the reversible viscosity 154 from a low shear strain (0.01 %) for 200 s, followed by a high shear strain (500 %) 155 measurement for 100 s at 37 °C. The testing frequency was fixed at a constant value of 5 156 rad·s⁻¹. Ten low-to-high shear strain cycles were measured in this process using an Anton Paar 157 MCR 302 rheometer.

158 Determination of hydrogel shear modulus and shear strength

The shear modulus (storage modulus G' and loss modulus G'') of the Fe³⁺-GSH crosslinked 159 hydrogel (Fe 300) was measured via a frequency sweep using an MCR 302 rheometer (Anton 160 Paar). This method was set with a 25 mm parallel plate at 37 °C, 1.5 mm gap, from 1-100 rad/s 161 162 under 5 % amplitude. G' and G'' were determined at 37 °C over a shear strain range of 0-500 % with a constant angular frequency (5 rad \cdot s⁻¹). Every 1.0 mL volume of Fe³⁺-GSH gel was 163 injected onto the sample plate and slightly pressed by a 25 mm parallel plate geometry with 164 a gap of 1.5 mm. Hyaluronic acid with the same amount of HCl solution only was measured as 165 166 a control for both shear modulus and shear strain.

167 Molecular mechanism study

168 ⁵⁷Fe Mössbauer spectroscopy was applied to study iron chelation and valence. Measurements were carried out using acrylic absorber discs (area: 1.8 cm²) loaded with a 169 170 dried gel sample to achieve a Mössbauer thickness of 1. The 14.4 keV y-rays were supplied by the cascade decay of 25 mCi ⁵⁷Co in Rh matrix source, oscillated at constant acceleration by a 171 172 SeeCo W304 drive unit, detected using a SeeCo 45431 Kr proportional counter operating with 173 1.745 kV bias voltage applied to the cathode. All measurements were carried out at 293 K over 174 a velocity range of ±6 mm·s⁻¹, and were calibrated relative to α -Fe foil. Spectral data were 175 fitted using the Recoil software package, using a single Lorentzian line shape necessitated by 176 the low signal/noise ratio obtained for the sample (indicative of its low Fe content).

177 Cellular tolerability study

ATDC 5 chondrocytes were cultured (37 °C, 5% CO₂) in a mixed medium of Dulbecco's modified Eagle's medium (DMEM) and Ham's F12 medium (1:1 in volume), supplemented with 5% fetal bovine serum (FBS), and 1 % penicillin-streptomycin. A defined amount of selfhealing gel was transferred into individual wells of a 96-well-plate and diluted by cell culture medium to a final concentration of 0 μ L (tissue culture plastics, TCPs), 5 μ L, 10 μ L, 20 μ L, 30 μ L, 40 μ L and 50 μ L per well, followed by addition of 100 μ L cell suspension (5×10⁴ cells/mL) in each (n=4). The cell viability was quantified by Alamar blue assay after 1-day, 3-day, 5-day
culture. Cells cultured on TCPs were set as the control group.

186 MMP-13 inhibition study with MMP-13–supplemented solution

187 The self-healing gel, as well as an HA solution and a commercial HA gel for OA injection, 188 OSTENIL® PLUS (both with the same HA concentration as the self-healing gel), were added to 189 deionised water (×4). Then, 20 µL of each sample was added to individual wells of a 96-well 190 plate, followed by adding 80 μ L H₂O per well. Pro-MMP 13 was activated following the 191 manufacturer protocol. Briefly, 5 µL MMP-13 (10 µg MMP-13/20 µL sample) was dissolved in 192 a p-aminophenyl mercuric acetate (AMPA) working solution (1 mM) to 1 μ g/mL and then 193 incubated at 37 °C for 40 min. Activated MMP-13 was diluted with AMPA solution (2 mM) to 194 25 ng/mL and then immediately added into the sample wells (each containing 100 μ L of the 195 sample), corresponding to a final MMP-13 concentration of 12.5 ng/mL to cover the enzymatic 196 concentration (6 ng/mL) recorded in synovial fluid samples of advanced OA patients (Heard et 197 al., 2012). Deionised water with an equal volume of APMA solution (2 mM) was set as the 198 blank, and deionised water with an equal volume of activated MMP-13 was set as the none 199 treatment group. After 12-hour or 24-hour incubation, MMP-13 activity was quantified via 200 fluorometric assay (Fluorometric Green, ab112146, Abcam) (Liang et al., 2018). 50 μL of each 201 sample was pipetted into a new 96-well-plate, followed by 50 µL of MMP Green Substrate 202 working solution. MMP 13-activity was recorded in fluorescence after 1-hour reaction in dark 203 at 37 °C using a microplate reader (Thermo Scientific Varioskan® Flash, Ex/Em=490/525 nm).

204 MMP-13 regulation study with patient collected synovial fluid


205 Synovial fluid (SF) samples were collected from late-stage osteoarthritic patients at Chapel 206 Allerton Hospital (Leeds, UK) under ethical approval granted by the National Research Ethics 207 Committee (ethical approval number: 07/Q1205/27). SF samples were stored at -80 °C until 208 use. A fluorometric assay kit (Fluorometric Green, ab112146) was used to measure the total 209 proteolytic activity in both SF and hydrogel-incubated SF samples. SF samples were diluted with the MMP assay buffer (×4), and the final Fe³⁺-GSH crosslinked gel dose was increased 210 (×4). 50 μ L of diluted SF were mixed with 40 μ L of Fe³⁺-GSH crosslinked gel, and 10 μ L of 211 212 deionised water was supplemented in each well to achieve a final concentration of 100 μ L/mL 213 [Fe³⁺-GSH crosslinked gel/solution]. The fluorometric assay was conducted after 24-hour 214 incubation following the same assay protocol reported for MMP-13 activity measurement.

215 Statistical analysis

All the samples were tested with at least three replicates ($n \ge 3$) and presented as Mean±SD. Statistical significance level was calculated through one-way ANOVA with a p-value at 0.05. Final statistical results were presented as *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001, ****p≤0.0001.

219 Results and discussion

220 Attempts to create hydrogels from HA (2 wt.%) and varying amounts of the Fe³⁺-GSH 221 complex (10 mg/mL) were conducted, and the optimal hydrogel was formed from 300 µL Fe³⁺-GSH complex (10 mg/mL) and 1 mL HA solution (2 wt.%). A significant decrease in viscosity 222 was observed with increasing shear rate from 0.01 Hz (14,400 Pa·s) to 4 Hz (37 Pa·s), whereas 223 224 the viscosity remained constant at shear rates between 4 Hz and 100 Hz (Fig. 1a). Compared 225 with the other materials created, the stability in hydrogel viscosity suggested a balanced 226 coordination at a Fe³⁺-GSH crosslinker concentration of 300 µL per mL of HA solution. On the 227 other hand, in the HA solution control groups, replacement of the Fe-GSH complex with the 228 HCl solution resulted in significantly lower viscosity(Fig. 1b), whereby no significant viscosity 229 variation was observed across the control groups.




230

Fig. 1 Flow curve of aqueous solutions supplemented with (a) either varied Fe³⁺-GSH complex/HA ratio
 or (b) varied concentration of HA, enlarged within the red box.

233

The iron oxidation state in the optimal hydrogel (Fe 300) was ferric (Fe³⁺) occupying octahedral coordination (Dyar et al., 2006)) ((Khalil et al., 2013), as determined by ⁵⁷Fe Mössbauer spectroscopy (**Fig. 2**), which also confirmed the chelation of Fe³⁺ to HA. The confirmed Fe³⁺ state in the hydrogel therefore speaks against a GSH-induced reduction to Fe²⁺ and the consequent generation of toxic reactive oxygen species, supporting the safe
injectability of the HA hydrogel in the OA site. In light of these characteristics, the
aforementioned hydrogel Fe 300 was chosen for further investigation.

241



242

243Fig. 2 Fitted ⁵⁷Fe Mössbauer spectrum of dry Fe³⁺-GSH gel at 293 K, relative to thin α-Fe foil. The clear244presence of a doublet attributable to paramagnetic Fe³⁺ can be observed, despite the low signal/noise245ratio due to the low abundance of Fe³⁺-GSH content in the gel. Fitted centre shift (δ) = 0.41 ± 0.02 mm246s⁻¹ and quadrupole splitting (Δ) = 0.72 ± 0.02 mm s⁻¹ with HWHM linewidth = 0.21 ± 0.02 mm s⁻¹.

247

258

248 A much higher G' value (120 Pa) was recorded for the Fe 300 gel that contained the Fe^{3+} -249 GSH crosslinker, compared to the HCI-HA control (10 Pa), again indicating that Fe-coordination 250 to HA enables gel formation. Constant storage (G'= 120 Pa) and loss (G"= 70 Pa) moduli of the 251 self-healing gel were successfully measured in frequency sweep mode, confirming a predominantly elastic behaviour in the range of 1-40 rad·s⁻¹, whilst the material elasticity was 252 253 found to decrease at the increased angular frequency (Fig. 3a). Although the storage modulus 254 is reduced compared to the chemically crosslinked HA hydrogel (G'=300 Pa), the elastic range 255 was much greater (angular frequency: 1-10 rad·s⁻¹) compared to the latter care (Gao et al., 256 2019). This behaviour illustrates the homogeneous nature of the gel. Conversely, the HCl-HA 257 control sample presented an obvious decrease in moduli from high to low frequency (Fig. 3b).




Fig. 3 Shear modulus of Fe³⁺-GSH hydrogel (a) and ctrl 300 samples (b) recorded during the frequency
 sweep.

Fig. 4 reveals the variability of dynamic shear modulus under shear strain (0.01-500 %) for the Fe³⁺-GSH crosslinked gel. A predominantly elastic gel response was observed up to 300 % shear strain, whereby both the storage and loss moduli remained constant when up to 80 % shear strain was applied with 5 rad/s (0.8 Hz) frequency.






Fig. 4 Shear modulus of Fe³⁺-GSH gel measured via strain sweep.

These results demonstrate mechanical compliance of the hydrogel with the ranges of shear
strain (up to 1 %) and frequency (0.5-2.0 Hz) observed *in vivo* in both connective and fatty
tissues (Yoo et al., 2011). In line with previous results, the storage modulus of the Fe³⁺-GSH
coordinated gel was found to be greater (105 Pa) than that of the hyaluronic acid control (70
Pa, Fig. S1), demonstrating increased mechanical competence.
After 10 cycling tests from low shear strain to high strain, Fe³⁺-GSH crosslinked gels

presented a stable complex viscosity in the range of 37-42 Pa·s and 12-16 Pa·s, respectively
(Fig. 5 blue).






Fig. 5 Dynamic time-dependent viscosity measurement of the initial (blue) and degraded (grey)
 Fe³⁺-GSH gel.

This dynamic reversible property confirms that Fe^{3+} -GSH crosslinked gels are self-healing materials. The profound degradability of Fe^{3+} -GSH crosslinked hydrogel in aqueous solution was confirmed by the decreased viscosity to 0.1-10 Pa·s after being incubated at 37 °C for 5 days (**Fig. 5 grey**). The transition from the HA solution to the Fe^{3+} -GSH crosslinked self-healing hydrogel was presented in **Fig. 6a&b**. **Fig. 6c** reveals the injectable property of this self-healing hydrogel, and the fact that the material can be absorbed (step 1) by a syringe and then be injected through the syringe tip (step 2), before undergoing extensive elongation (step 3).





Fig. 6 Illustration of Fe³⁺-GSH hydrogel formation. (a): Molecular configuration and physical
 appearance of the HA solution; (b): Proposed coordination structure within, and physical appearance
 of, the Fe³⁺-GSH hydrogel. (c): Macroscopic properties of Fe³⁺-GSH gel, being loaded up (step 1),
 injected (step 2) and stretched (step 3).

290

285

We could also observe the sticky property of this self-healing hydrogel in step 3; in line with previous viscosity analysis, the adhesive properties of HA were enhanced by Fe^{3+} -GSH induction. This feature is key to enable confined application and adhesion of the gel to cartilage, aiming to stabilise the joint cavity and to reduce bone-to-bone friction, which is essential to preserve the cartilage interface (Abubacker et al., 2018).

The dose of Fe³⁺-GSH crosslinked HA gel that is tolerated by ATDC 5 chondrocytes was then determined *in vitro* via Alamar Blue assay (**Fig. 7**). As expected, the hydrogel reveals a dosedependent impact on cellular metabolic activity. At day 1, the lower dose (e.g. 5 and 10 μ L) of Fe³⁺-GSH crosslinked HA gel did not show significant effect compared to the case of the TCPs control group (p > 0.05). However, the high dose groups (e.g. > 20 μ L) significantly reduced the metabolic activity of ATCD-5 cells compared to the control group (p < 0.01, 0.001, 0.001, 0.05, respectively). Clearly, no significant difference in cellular activity was observed following 1-day cell culture in either TCP or lower doses of Fe³⁺-GSH crosslinked hydrogel (with both 5 μ L and 10 μ L dose). At day 5, only the 5 μ L group was well tolerated (p > 0.05), but all the other higher dose groups (e.g. > 10 μ L) were significantly detrimental to the metabolic activity of the cells compared to the control group (p ≤ 0.05, 0.001, 0.0001 respectively).



307

308 Fig.7 ATDC 5 cells viability when growing with Fe³⁺-GSH gel after day 1 and 5. No significant 309 differences are labelled with "NS". Significant differences are observed in each group with respect to the TCPs group at the same time point (n=4). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. 310 311 312 Furthermore, the increase in metabolic activity recorded from day 1 to day 5 in ATDC 5 cells cultured with 5-30 µL hydrogel (Table 1) was similar to that measured in cells treated with the 313 TCPs control group (7.9 times). This observation indicates that decreased doses (e.g. \leq 30 μ L) 314 of Fe³⁺-GSH hydrogel did not affect the cell proliferation (e.g. cell doubling) in this time 315 316 window, in contrast to the case where higher doses (e.g. \ge 40 μ L) were applied. Given that the 317 initial cell seeding density (5,000 cells per well) was maintained across all hydrogel groups (5-50 μ l), the reduced cellular metabolic activity observed with increased gel volume (> 30 μ l) is 318 319 likely attributed to the relatively small number of cells cultured with increased sample dosages. 320

Table 1 Variation in ATDC 5 cellular activity over 5-day culture with varied hydrogel dosage.

Hydrogel dosage	Average cellular activity increase
0 μl (TCP)*	7.9
5 μL	10.5
10 µL	7.0
20 µL	8.8
30 µL	7.4
40 µL	0.1
50 μL	0

321

322 323 * Cells cultured in hydrogel-free Tissue Culture Plastic (TCP).

This observation may suggest that the gels under 30 µL dose were temporarily toxic after 1day. However, the proliferation of the remaining ATDC 5 cells was not affected, an explanation which is supported by the optical microscope images of cells cultured for 1 (**Fig. S2**) and 5 days (**Fig. S3**). In contrast, no cellular tolerability was observed in both 40 and 50 µL hydrogel groups over 5 days.

329 The capability of the Fe³⁺-GSH crosslinked hydrogels to inhibit proteolytic activity was then 330 assessed, whereby MMP-13 was selected as a well-known upregulated protease in late-stage 331 OA. By selecting MMP-13-supplemented aqueous solutions as a defined in vitro environment, incubation of Fe³⁺-GSH hydrogel resulted in a reduction of MMP-13 activity after 12 hours 332 333 (95.7±3.4 %). A significant reduction in MMP-13 activity (92.9±1.4 %) was recorded after 24 334 hours, compared to the positive control group (p<0.001) (Fig. 8). On the other hand, no 335 significant activity difference was observed between MMP-13-supplemented solutions and 336 the same solutions following incubation with either soluble, complex-free GSH (103.1±7.6 %) 337 (Gao et al., 2020) or native HA after 24 hours (98.5±5.0 %). In OSTENIL® PLUS, no reduction in 338 MMP-13 activity was seen after 12 hours, but a significant reduction (p<0.05) in activity was 339 observed after 24 hours (96.1±1.7 %), with respect to the pristine MMP-13 solution. A 340 comparison between the Fe³⁺-GSH crosslinked gel and OSTENIL® PLUS reveals that increased 341 MMP-13 inhibition occurred in the presence of the Fe³⁺-GSH crosslinked hydrogel after 12 342 hours (p<0.01), which was maintained after 24 hours (p<0.05). These results provide indirect 343 evidence that the hydrogel-induced MMP-13 inhibition was achieved via chelation of 344 respective iron sites with free sulfhydryl groups of active MMPs, rather than by complexation 345 of the free zinc sites of active MMPs (Liang et al., 2018) with either the hydrogel's or GSH's 346 sulfhydryl groups, on the one hand or HA's carboxylic groups on the other hand. These observations support the key role played by the Fe³⁺-GSH complex in both hydrogel 347 348 crosslinking and MMP inhibition.

349






Fig.8 Variation of MMP-13 activity in MMP-13–supplemented solutions after 12-hour (a) and 24-hour
 (b) incubation with either the Fe³⁺-GSH crosslinked hydrogel, an HA solution or the OSTENIL[®] PLUS
 commercial injection. Data are presented as Mean ± SD, statistical analysis was carried out between
 each two groups and labelled as *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001, otherwise means no significant
 difference at p=0.05 level.

356

357 A sample of synovial fluid (S162) collected from patients with late-stage OA was used to investigate the MMP-regulating capability of the Fe³⁺-GSH crosslinked gel in near-physiologic 358 359 conditions, and to further corroborate the previous findings obtained for hydrogel-mediated MMP-13 inhibition in a defined in vitro environment, as the overall proteolytic activity, 360 including MMP-1, -2, -3, -7, -8, -9 and -13, were confirmed to have increased activity in 361 362 advanced OA (Yoshihara et al., 2000). Fig. 9 reveals that lower overall MMP activity and smaller standard deviations were observed for the Fe³⁺-GSH crosslinked gel (81.0±7.5 %) 363 compared to the native SF group (100.0±17.6 %), with a p-value of 0.0942. Although OSTENIL® 364 PLUS presented a lower average value of activity (92.3±27.3 %) compared to native SF 365 366 (p=0.6528), a larger standard deviation was recorded for this group versus both SF and the Fe³⁺-GSH crosslinked gel. 367




Fig.9 Variation of MMP activity recorded in a patient collected SF sample after 24-hour incubation

368

369 370

with either the Fe³⁺-GSH crosslinked hydrogel or the OSTENIL® PLUS commercial injection (n=4). The SF sample was collected from a patient (donor S162) with late-stage OA.

371 372

The results obtained with the clinical SF sample in the absence of MMP activating reagents, i.e. APMA, therefore confirm the new MMP inhibition functionality introduced in the Fe³⁺-GSH crosslinked hydrogel. These results therefore support the use of this material as both a mechanically-competent hydrogel and as a mediator of MMP regulation for OA therapy. The confirmation of hydrogel performance with patient collected samples also lay down new possibilities on the use of human synovial fluid for the preclinical evaluation of medical devices intended for osteoarthritis management, yet minimising reliance on animal testing.

380

381 Conclusions

A drug-free Fe³⁺-GSH crosslinked injectable hydrogel was prepared with integrated self-382 383 healing and MMP inhibition functionalities. The coordination mechanism to yield the hydrogel 384 was confirmed by shear frequency sweep tests, which revealed a storage modulus more than ten times higher than the loss modulus. ⁵⁷Fe Mössbauer spectroscopy revealed that Fe was 385 present in the hydrogel as octahedrally-coordinated Fe³⁺, so that risks of Fe²⁺-mediated ROS 386 387 generation and ROS-mediated toxicity were minimised, supporting the hydrogel applicability in biological environment. The hydrogel could hold up to 300% shear strain and presented a 388 389 stable complex viscosity (37-42 \rightarrow 12-16 Pa·s) after 10 cycling tests from low to high strain. In 390 vitro, the gel proved to be well tolerated by ATDC 5 chondrocytes and to support cell 391 proliferation during a five day-culture. Furthermore, the gel demonstrated the inhibition of 392 MMP activity after 24 hour-incubation in both an MMP-13–supplemented aqueous solution 393 and a patient collected sample of synovial fluid, in light of the metal-coordinating reaction 394 between thiol-complexed iron(III) and free sulfhydryl groups of active MMPs is exploited to 395 induce MMP inhibition. These results therefore demonstrate that the hydrogel's


biomechanical competence was successfully integrated with drug-free MMP regulation
 capability. The simple material design, together with the hydrogel's injectability, and
 biochemical and self-healing functionalities support further development of this system for
 drug-free OA therapies.

400

401 Acknowledgements

- 402 PAB acknowledges with thanks funding support from the UK Engineering and Physical Science
- 403 Research Council (EPSRC) under Grant EP/R020957/1, New Industrial Systems: Manufacturing
- 404 Immortality.

405 Graphical abstract



Fe-coordination to HA in aqueous environment generates an injectable, self-healing andbiomechanically viable gel and enables factor-free regulation of matrix metalloproteinases.

412 References

- Abubacker, S., McPeak, A., Dorosz, S. G., Egberts, P., & Schmidt, T. A. (2018). Effect of
 counterface on cartilage boundary lubricating ability by proteoglycan 4 and hyaluronan:
 Cartilage-glass versus cartilage–cartilage. *Journal of Orthopaedic Research*, *36*(11),
 2923–2931. https://doi.org/10.1002/jor.24104
- Blache, U., Stevens, M. M., & Gentleman, E. (2020). Harnessing the secreted extracellular
 matrix to engineer tissues. *Nature Biomedical Engineering*, 1–7.
 https://doi.org/10.1038/s41551-019-0500-6
- Burrage, P. S., Mix, K. S., & Brinckerhoff, C. E. (2006). Matrix metalloproteinases: Role in
 arthritis. *Frontiers in Bioscience*, *11*(1 P.447-888), 529–543.
 https://doi.org/10.2741/1817
- Chen, H., Cheng, R., Zhao, X., Zhang, Y. S., Tam, A., Yan, Y., Shen, H., Zhang, Y. S., Qi, J., Feng,
 Y., Liu, L., Pan, G., Cui, W., & Deng, L. (2019). An injectable self-healing coordinative
 hydrogel with antibacterial and angiogenic properties for diabetic skin wound repair. *NPG Asia Materials*, *11*(1). https://doi.org/10.1038/s41427-018-0103-9
- Clark, A. Y., Martin, K. E., García, J. R., Johnson, C. T., Theriault, H. S., Han, W. M., Zhou, D. W.,
 Botchwey, E. A., & García, A. J. (2020). Integrin-specific hydrogels modulate transplanted
 human bone marrow-derived mesenchymal stem cell survival, engraftment, and
 reparative activities. *Nature Communications*, *11*(1), 1–14.
 https://doi.org/10.1038/s41467-019-14000-9
- Dernek, B., Duymus, T. M., Koseoglu, P. K., Aydin, T., Kesiktas, F. N., Aksoy, C., & Mutlu, S.
 (2016). Efficacy of single-dose hyaluronic acid products with two different structures in
 patients with early-stage knee osteoarthritis. *Journal of Physical Therapy Science*, 28(11),
 3036–3040. https://doi.org/10.1589/jpts.28.3036
- 436 Dyar, M. D., Agresti, D. G., Schaefer, M. W., Grant, C. A., & Sklute, E. C. (2006). Mössbauer
 437 Spectroscopy of Earth and Planetary Materials. *Annual Review of Earth and Planetary*438 *Sciences*, *34*(1), 83–125. https://doi.org/10.1146/annurev.earth.34.031405.125049
- Gao, Z., Carames-mendez, P., Xia, D., Pask, C. M., Mcgowan, P. C., Bingham, P. A., Scrimshire,
 A., Tronci, G., & Thornton, P. D. (2020). *The facile and additive-free synthesis of a cell- friendly iron(III)–glutathione complex*. *49*, 10574–10579.
 https://doi.org/10.1039/d0dt02331k
- Gao, Z., Golland, B., Tronci, G., & Thornton, P. D. (2019). A redox-responsive hyaluronic acidbased hydrogel for chronic wound management. *Journal of Materials Chemistry B*, 7(47),
 7494–7501. https://doi.org/10.1039/c9tb01683j
- Heard, B. J., Martin, L., Rattner, J. B., Frank, C. B., Hart, D. A., & Krawetz, R. (2012). Matrix
 metalloproteinase protein expression profiles cannot distinguish between normal and
 early osteoarthritic synovial fluid. *BMC Musculoskeletal Disorders*, 13(1), 1.

449 https://doi.org/10.1186/1471-2474-13-126

- Hu, X., Gao, Z., Tan, H., Wang, H., Mao, X., & Pang, J. (2019). An Injectable Hyaluronic AcidBased Composite Hydrogel by DA Click Chemistry With pH Sensitive Nanoparticle for
 Biomedical Application. *Frontiers in Chemistry*, 7(July), 1–11.
 https://doi.org/10.3389/fchem.2019.00477
- Huang, W., Wang, Y., Chen, Y., Zhao, Y., Zhang, Q., Zheng, X., Chen, L., & Zhang, L. (2016).
 Strong and Rapidly Self-Healing Hydrogels: Potential Hemostatic Materials. *Advanced Healthcare Materials*, 5(21), 2813–2822. https://doi.org/10.1002/adhm.201600720
- Khalil, M. I., Al-Zahem, A. M., & Al-Qunaibit, M. H. (2013). Synthesis, characterization,
 mössbauer parameters, and antitumor activity of Fe(III) curcumin complex. *Bioinorganic Chemistry and Applications, 2013*, 1–5. https://doi.org/10.1155/2013/982423
- Kim, K. S., Choi, H. M., Lee, Y. A., Choi, I. A., Lee, S. H., Hong, S. J., Yang, H. I., & Yoo, M. C.
 (2011). Expression levels and association of gelatinases MMP-2 and MMP-9 and
 collagenases MMP-1 and MMP-13 with VEGF in synovial fluid of patients with arthritis. *Rheumatology International*, *31*(4), 543–547. https://doi.org/10.1007/s00296-0101592-1
- Kotevoglu, N., lyibozkurt, P. C., Hiz, O., Toktas, H., & Kuran, B. (2006). A prospective
 randomised controlled clinical trial comparing the efficacy of different molecular weight
 hyaluronan solutions in the treatment of knee osteoarthritis. *Rheumatology International*, 26(4), 325–330. https://doi.org/10.1007/s00296-005-0611-0
- Lee, E. J., Kang, E., Kang, S. W., & Huh, K. M. (2020). Thermo-irreversible glycol
 chitosan/hyaluronic acid blend hydrogel for injectable tissue engineering. *Carbohydrate Polymers*, 244(May), 116432. https://doi.org/10.1016/j.carbpol.2020.116432
- Li, H., Wang, D., Yuan, Y., & Min, J. (2017). New insights on the MMP-13 regulatory network
 in the pathogenesis of early osteoarthritis. *Arthritis Research & Therapy*, *19*(1), 248.
 https://doi.org/10.1186/s13075-017-1454-2
- Li, S., Pei, M., Wan, T., Yang, H., Gu, S., Tao, Y., Liu, X., Zhou, Y., Xu, W., & Xiao, P. (2020). Selfhealing hyaluronic acid hydrogels based on dynamic Schiff base linkages as biomaterials. *Carbohydrate Polymers*, 250(May), 116922.
 https://doi.org/10.1016/j.carbpol.2020.116922
- Liang, H., Russell, S. J., Wood, D. J., & Tronci, G. (2018). A hydroxamic acid-methacrylated
 collagen conjugate for the modulation of inflammation-related MMP upregulation. *Journal of Materials Chemistry B, 6*(22), 3703–3715.
 https://doi.org/10.1039/c7tb03035e
- Liu, L., Xiang, Y., Wang, Z., Yang, X., Yu, X., Lu, Y., Deng, L., & Cui, W. (2019). Adhesive liposomes
 loaded onto an injectable, self-healing and antibacterial hydrogel for promoting bone
 reconstruction. *NPG Asia Materials*, *11*(1). https://doi.org/10.1038/s41427-019-0185-z

- Liu, M., Zeng, X., Ma, C., Yi, H., Ali, Z., Mou, X., Li, S., Deng, Y., & He, N. (2017). Injectable
 hydrogels for cartilage and bone tissue engineering. *Bone Research*, 5(November 2016).
 https://doi.org/10.1038/boneres.2017.14
- Loynachan, C. N., Soleimany, A. P., Dudani, J. S., Lin, Y., Najer, A., Bekdemir, A., Chen, Q.,
 Bhatia, S. N., & Stevens, M. M. (2019). Renal clearable catalytic gold nanoclusters for in
 vivo disease monitoring. *Nature Nanotechnology*, *14*(9), 883–890.
 https://doi.org/10.1038/s41565-019-0527-6
- Paquet, C., De Haan, H. W., Leek, D. M., Lin, H. Y., Xiang, B., Tian, G., Kell, A., & Simard, B.
 (2011). Clusters of superparamagnetic iron oxide nanoparticles encapsulated in a
 hydrogel: A particle architecture generating a synergistic enhancement of the T2
 relaxation. ACS Nano, 5(4), 3104–3112. https://doi.org/10.1021/nn2002272
- Shi, Y., Wang, M., Ma, C., Wang, Y., Li, X., & Yu, G. (2015). A Conductive Self-Healing Hybrid
 Gel Enabled by Metal-Ligand Supramolecule and Nanostructured Conductive Polymer. *Nano Letters*, *15*(9), 6276–6281. https://doi.org/10.1021/acs.nanolett.5b03069
- 500 Slepecky, R. A. (1967). Human Synovial Fluid : Detection of a New Component. *Science*,
 501 155(3764), 839–842. https://doi.org/10.1126/science.155.3764.839
- Spicer, C. D. (2020). Hydrogel scaffolds for tissue engineering: The importance of polymer
 choice. In *Polymer Chemistry* (Vol. 11, Issue 2, pp. 184–219). Royal Society of Chemistry.
 https://doi.org/10.1039/c9py01021a
- Stevens, M. M., & George, J. H. (2005). Exploring and engineering the cell surface interface.
 Science, *310*(5751), 1135–1138. https://doi.org/10.1126/science.1106587
- Tang, C. L., Jayne, D. G., Seow-Choen, F., Ng, Y. Y., Eu, K. W., & Mustapha, N. (2006). A
 randomized controlled trial of 0.5% ferric hyaluronate gel (intergel) in the prevention of
 adhesions following abdominal surgery. *Annals of Surgery*, 243(4), 449–455.
 https://doi.org/10.1097/01.sla.0000207837.71831.a2
- Valachová, Katarína, Baňasová, M., Toposká, D., Sasinková, V., Juránek, I., Collins, M. N., &
 Šoltés, L. (2015). Influence of tiopronin, captopril and levamisole therapeutics on the
 oxidative degradation of hyaluronan. *Carbohydrate Polymers*, *134*, 516–523.
 https://doi.org/10.1016/j.carbpol.2015.07.029
- Valachová, Katarina, Topol'ská, D., Mendichi, R., Collins, M. N., Sasinková, V., & Šoltés, L.
 (2016). Hydrogen peroxide generation by the Weissberger biogenic oxidative system
 during hyaluronan degradation. *Carbohydrate Polymers*, *148*, 189–193.
 https://doi.org/10.1016/j.carbpol.2016.04.063
- Wang, H., Jordan, V. C., Ramsay, I. A., Sojoodi, M., Fuchs, B. C., Tanabe, K. K., Caravan, P., &
 Gale, E. M. (2019). Molecular Magnetic Resonance Imaging Using a Redox-Active Iron
 Complex. Journal of the American Chemical Society, 141(14), 5916–5925.
 https://doi.org/10.1021/jacs.9b00603

- Wang, M., Sampson, E. R., Jin, H., Li, J., Ke, Q. H., Im, H. J., & Chen, D. (2013). MMP13 is a
 critical target gene during the progression of osteoarthritis. *Arthritis Research and Therapy*, 15(1), 1–11. https://doi.org/10.1186/ar4133
- Yoo, L., Gupta, V., Lee, C., Kavehpore, P., & Demer, J. L. (2011). Viscoelastic properties of
 bovine orbital connective tissue and fat: Constitutive models. *Biomechanics and Modeling in Mechanobiology*, *10*(6), 901–914. https://doi.org/10.1007/s10237-0100281-z
- Yoshihara, Y., Nakamura, H., Obata, K., Yamada, H., Hayakawa, T., Fujikawa, K., & Okada, Y.
 (2000). Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial
 fluids from patients with rheumatoid arthritis or osteoarthritis. *Annals of the Rheumatic Diseases*, 59(6), 455 LP 461. https://doi.org/10.1136/ard.59.6.455
- Yu, W., Zhu, Y., Li, H., & He, Y. (2019). An injectable quercetin-loaded hydrogel with cartilage protection and immunomodulatory properties for articular cartilage repair. ACS Applied
 Bio Materials. https://doi.org/10.1021/acsabm.9b00673
- Zamboni, F., Keays, M., Hayes, S., Albadarin, A. B., Walker, G. M., Kiely, P. A., & Collins, M. N.
 (2017). Enhanced cell viability in hyaluronic acid coated poly(lactic-co-glycolic acid)
 porous scaffolds within microfluidic channels. *International Journal of Pharmaceutics*,
 532(1), 595–602. https://doi.org/10.1016/j.ijpharm.2017.09.053
- Zamboni, F., Ryan, E., Culebras, M., & Collins, M. N. (2020). Labile crosslinked hyaluronic acid
 via urethane formation using bis(β-isocyanatoethyl) disulphide with tuneable
 physicochemical and immunomodulatory properties. *Carbohydrate Polymers, 245*(May),
 116501. https://doi.org/10.1016/j.carbpol.2020.116501
- Zhang, Y., Yu, J., Ren, K., Zuo, J., Ding, J., & Chen, X. (2019). Thermosensitive Hydrogels as
 Scaffolds for Cartilage Tissue Engineering [Review-article]. *Biomacromolecules*, 20(4),
 1478–1492. https://doi.org/10.1021/acs.biomac.9b00043

548